Step 1 topics → Reproductive → Leiomyoma (Uterine Fibroid)

Leiomyoma (Uterine Fibroid)

USMLE Step 1 trap: Incorrectly believes fibroids commonly transform into leiomyosarcoma. Leiomyosarcoma arises de novo from myometrium, not from malignant transformation of leiomyomas; the risk of a fibroid becoming malignant is extremely low (<0.5%).

Leiomyomas — fibroids — are the most common benign uterine tumors, made of smooth muscle, and they're a guaranteed topic on USMLE Step 1. The exam tests them from multiple angles: pure recall (what are they, what drives growth), clinical presentation (which location causes which symptom), and management logic (why GnRH agonists work, when surgery is needed). Knowing that fibroids are estrogen-sensitive is the foundation everything else builds on — growth during reproductive years, enlargement in pregnancy, shrinkage after menopause.

The trickiest part of this topic is location-symptom mapping. Students often treat all fibroids as interchangeable, but the exam absolutely distinguishes submucosal from intramural from subserosal. Submucosal fibroids distort the endometrial cavity and are the key culprits for heavy menstrual bleeding and infertility. Subserosal fibroids bulge outward and can compress adjacent structures like the bladder or rectum. Getting this wrong on a vignette is common and avoidable.

The other classic trap on USMLE Step 1 is the malignant transformation question. Students assume that because leiomyosarcoma exists, fibroids must transform into it. They don't. Leiomyosarcoma arises de novo from the myometrium — a fibroid becoming malignant is vanishingly rare. Don't let a question about a rapidly growing uterine mass after menopause trick you into thinking it started as a fibroid; that vignette is describing leiomyosarcoma, not transformed fibroid.

From real student decks
57%have cards covering this topic
35%have mature cards

Common misconceptions

Common mistake
Wrong: Leiomyomas (fibroids) frequently undergo malignant transformation into leiomyosarcoma.
Right: Leiomyosarcoma arises de novo from myometrium, not from malignant transformation of leiomyomas; the risk of a fibroid becoming malignant is extremely low (<0.5%).
Leiomyosarcoma does not arise from malignant transformation of fibroids — it develops de novo from myometrial smooth muscle cells. The risk of a fibroid itself becoming malignant is under 0.5%, making it essentially a non-issue clinically. When you see a vignette about a rapidly enlarging uterine mass in a postmenopausal woman, think leiomyosarcoma as a separate entity, not a fibroid gone bad.
Common mistake
Wrong: All fibroid locations equally cause abnormal uterine bleeding.
Right: Submucosal fibroids are most likely to cause abnormal uterine bleeding and infertility because they distort the endometrial cavity; subserosal fibroids rarely cause bleeding.
Not all fibroid locations cause bleeding equally — location determines the dominant symptom. Submucosal fibroids project into the endometrial cavity, disrupting the endometrial lining and impairing implantation, which is why they cause the heaviest bleeding and are the most likely to cause infertility. Subserosal fibroids sit on the outer uterine surface and rarely affect the endometrium at all, so bleeding is not their signature presentation.
Common mistake
Wrong: Fibroids grow under progesterone stimulation and shrink with estrogen.
Right: Fibroids are estrogen-sensitive and grow during reproductive years and pregnancy; they shrink after menopause when estrogen levels fall.
Fibroids are driven by estrogen, not progesterone — this is a classic reversal mistake. The clinical evidence is straightforward: fibroids grow during the high-estrogen reproductive years, enlarge during pregnancy, and reliably shrink after menopause when estrogen drops. GnRH agonists like leuprolide work precisely because they suppress estrogen; if progesterone were the driver, progestin therapy would be the mainstay of treatment.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the definition of leiomyomas — benign smooth muscle tumors of the myometrium — and that they are estrogen-sensitive, growing during reproductive years and shrinking after menopause.
  2. Understand how fibroid location determines symptoms: submucosal fibroids distort the endometrial cavity causing heavy bleeding and infertility, intramural fibroids cause bulk symptoms and menorrhagia, and subserosal fibroids cause pressure effects on adjacent organs like the bladder.
  3. Know the management spectrum: GnRH agonists (like leuprolide) temporarily shrink fibroids by inducing a hypoestrogenic state, myomectomy preserves fertility, and hysterectomy is definitive treatment.

Can you avoid these mistakes?

A 38-year-old woman presents with heavy menstrual bleeding and infertility. Pelvic ultrasound shows a uterine fibroid. Which fibroid location is most likely responsible for both of her symptoms, and why?
A patient with symptomatic fibroids is started on leuprolide (a GnRH agonist) preoperatively. Explain the mechanism by which this medication reduces fibroid size.
A 55-year-old postmenopausal woman presents with a rapidly enlarging uterine mass. Her physician says this is unlikely to be a transformed fibroid. Why is malignant transformation of leiomyoma not the correct explanation here, and what is the more likely diagnosis?
A medical student says 'fibroids in the outer wall of the uterus are causing this patient's heavy periods.' What is wrong with this reasoning, and which fibroid type would you correctly implicate?

Related topics

Gonadal Differentiation (SRY, MIS, Testosterone) Müllerian vs Wolffian Duct Derivatives 5α-Reductase Deficiency Complete Androgen Insensitivity Syndrome (CAIS)

See how your Anki deck covers this topic.

Upload your deck for a free audit →